Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 7, 2014; 20(41): 15200-15215
Published online Nov 7, 2014. doi: 10.3748/wjg.v20.i41.15200
Published online Nov 7, 2014. doi: 10.3748/wjg.v20.i41.15200
Immune-modulating therapy in acute pancreatitis: Fact or fiction
Karolina Akinosoglou, Charalambos Gogos, Department of Internal Medicine and Infectious Diseases, University General Hospital of Patras, 26504 Rio, Greece
Author contributions: Akinosoglou K and Gogos C performed literature searches and reviewed appropriate articles; Akinosoglou K wrote the manuscript and drew figures; Gogos C critically corrected the manuscript.
Correspondence to: Karolina Akinosoglou, MD, Department of Internal Medicine and Infectious Diseases, University General Hospital of Patras, 5th Floor, 26504 Rio, Greece. akin@upatras.gr
Telephone: +30-2610-999582 Fax: +30-2610-999582
Received: March 16, 2014
Revised: May 21, 2014
Accepted: June 14, 2014
Published online: November 7, 2014
Processing time: 239 Days and 0.8 Hours
Revised: May 21, 2014
Accepted: June 14, 2014
Published online: November 7, 2014
Processing time: 239 Days and 0.8 Hours
Core Tip
Core tip: Acute pancreatitis is a common entity with significant mortality worldwide. Treatment remains non-specific and mainly supportive, mostly focusing on intensive care. Presence of inflammatory response syndrome during AP has driven recent immune-modulating therapeutic attempts in experimental models, including cytokine, chemokine, immune cell and other inflammatory mediator blockade. Although initial data are promising, translation to clinical routine has been less encouraging. The authors attempt to elucidate whether and to what extent tampering with the immune burst triggered by acute pancreatitis could actually ensure better outcomes, or that remains a farfetched expectation.